Evidence map›Paper›PMID 27895114›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2017

In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1.

Y Anne Pak, Amanda J Long, William F Annes, Jennifer W Witcher, Mary Pat Knadler, Mosun A Ayan-Oshodi, Malcolm I Mitchell, Phillip Leese, Kathleen M Hillgren

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. PEPT1-mediated prodrug strategy for oral delivery of peramivir.Asian journal of pharmaceutical sciences · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Y Anne PakEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Y.A.P., A.J.L.,W.F.A., J.W.W., M.P.K., M.A.A.-O., M.I.M., K.M.H.); and Quintiles Transnational, Clinical Pharmacology, Overland Park, Kansas (P.L.) pak_youngeen_anne@lilly.com.
Amanda J LongEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Y.A.P., A.J.L.,W.F.A., J.W.W., M.P.K., M.A.A.-O., M.I.M., K.M.H.); and Quintiles Transnational, Clinical Pharmacology, Overland Park, Kansas (P.L.).
William F AnnesEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Y.A.P., A.J.L.,W.F.A., J.W.W., M.P.K., M.A.A.-O., M.I.M., K.M.H.); and Quintiles Transnational, Clinical Pharmacology, Overland Park, Kansas (P.L.).
Jennifer W WitcherEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Y.A.P., A.J.L.,W.F.A., J.W.W., M.P.K., M.A.A.-O., M.I.M., K.M.H.); and Quintiles Transnational, Clinical Pharmacology, Overland Park, Kansas (P.L.).
Mary Pat KnadlerEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Y.A.P., A.J.L.,W.F.A., J.W.W., M.P.K., M.A.A.-O., M.I.M., K.M.H.); and Quintiles Transnational, Clinical Pharmacology, Overland Park, Kansas (P.L.).
Mosun A Ayan-OshodiEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Y.A.P., A.J.L.,W.F.A., J.W.W., M.P.K., M.A.A.-O., M.I.M., K.M.H.); and Quintiles Transnational, Clinical Pharmacology, Overland Park, Kansas (P.L.).
Malcolm I MitchellEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Y.A.P., A.J.L.,W.F.A., J.W.W., M.P.K., M.A.A.-O., M.I.M., K.M.H.); and Quintiles Transnational, Clinical Pharmacology, Overland Park, Kansas (P.L.).
Phillip LeeseEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Y.A.P., A.J.L.,W.F.A., J.W.W., M.P.K., M.A.A.-O., M.I.M., K.M.H.); and Quintiles Transnational, Clinical Pharmacology, Overland Park, Kansas (P.L.).
Kathleen M HillgrenEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Y.A.P., A.J.L.,W.F.A., J.W.W., M.P.K., M.A.A.-O., M.I.M., K.M.H.); and Quintiles Transnational, Clinical Pharmacology, Overland Park, Kansas (P.L.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite peptide transporter 1 (PEPT1) being responsible for the bioavailability for a variety of drugs, there has been little study of its potential involvement in drug-drug interactions. Pomaglumetad methionil, a metabotropic glutamate 2/3 receptor agonist prodrug, utilizes PEPT1 to enhance absorption and bioavailability. In vitro studies were conducted to guide the decision to conduct a clinical drug interaction study and to inform the clinical study design. In vitro investigations determined the prodrug (LY2140023 monohydrate) is a substrate of PEPT1 with K

Indexed as

AcyclovirAdolescentAdultAgedAmino AcidsBiological TransportBridged Bicyclo Compounds, HeterocyclicCyclic S-OxidesDrug InteractionsFemaleHeLa CellsHumansMaleMiddle AgedPeptide Transporter 1Prodrugs4-aminho-2-thiabicyclo(3.1.0)hexane-4,6-dicarboxylic acidAcyclovirAmino AcidsBridged Bicyclo Compounds, HeterocyclicCyclic S-Oxidesmetabotropic glutamate receptor 2metabotropic glutamate receptor 3Peptide Transporter 1pomaglumetad methionilProdrugsReceptors, Metabotropic GlutamateValacyclovirValine

Identifiers

PMID27895114
PMCPMC5267515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.